PEPG (PepGen Inc.) Pangali EV/EBITDA

This price visualization for PepGen Inc. (PEPG), which specializes in muscle pathology therapies and assists in the basic valuation of the asset, demonstrates the 0.00 indicator. The business relies on external contractors for drug production and testing, thereby minimizing its own capacities. Operational stability is ensured by the global distribution of raw material suppliers, which prevents any disruptions in the supply chains of biocomponent for laboratories.

The multiple combines market capitalization and net debt, comparing the total enterprise value with operating profit before depreciation and amortization to determine the real value of the business. For PepGen Inc. (PEPG), with its closed patent loop of the EDO platform, the current EV/EBITDA multiple reflects the market valuation of RNA therapy potential relative to current efficiency, where a downward trend on the chart signals an undervaluation of biopharmaceutical assets.